Therefore, ChE inhibitors are used to elevate ACh concentrations in the brains of AD patients, thereby potentially providing therapeutic benefit.[12] Prior research suggests that AChE exhibits greater substrate specificity than BChE in the human brain,[13] leading to the prevailing view that AChE inhibitors may offer more targeted therapeutic effects compared to BChE inhibitors. The gene discussed is BCHE; the disease is Alzheimer disease.